Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study
- PMID: 18588561
- DOI: 10.1111/j.1398-9995.2008.01724.x
Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study
Abstract
Background: Uncontrolled asthma is characterized by variability. Current asthma guidelines recommend focussing on the achievement and maintenance of control but few studies have examined in detail, using composite measures of control, the stability and potential duration of control once achieved. In this post-hoc analysis of the results of the Gaining Optimal Asthma controL (GOAL) study, we examine the association between the level of asthma control achieved during the step-up phase of the study and the stability of control experienced during the maintenance phase.
Methods: GOAL was a 1-year, randomized, stratified, double-blind study of 3421 patients with uncontrolled asthma, which compared salmeterol/fluticasone propionate combination with fluticasone propionate in achieving two composite, guideline-based measures of control: totally controlled and well-controlled asthma. We analysed the proportion and duration of time spent in control, the effect of treatment on asthma stability, and the impact of asthma control stability on unscheduled use of healthcare resources.
Results: In patients achieving well-controlled or totally controlled asthma, at least well-controlled asthma was maintained for a median of almost 3 and 6 months, and for more than 85% and 95% of weeks of follow-up, respectively. A high level of stability was confirmed in a Markov analysis investigating transitional probability of change in control status. Variability in control was associated with increased probability of an unscheduled healthcare resource use (odds ratio: 1.06, P < 0.001).
Conclusions: Most patients achieving guideline-defined control can maintain at least a similar level of control with regular, stable dosing, with little likelihood of losing control.
Similar articles
-
Asthma control over 3 years in a real-life study.Respir Med. 2009 Mar;103(3):348-55. doi: 10.1016/j.rmed.2008.10.015. Epub 2008 Nov 29. Respir Med. 2009. PMID: 19042115 Clinical Trial.
-
Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.Clin Ther. 2008 Aug;30(8):1492-504. doi: 10.1016/j.clinthera.2008.07.018. Clin Ther. 2008. PMID: 18803991 Clinical Trial.
-
Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study.J Allergy Clin Immunol. 2007 Nov;120(5):1036-42. doi: 10.1016/j.jaci.2007.07.016. Epub 2007 Nov 1. J Allergy Clin Immunol. 2007. PMID: 17935765 Clinical Trial.
-
Salmeterol/fluticasone propionate combination product in asthma. An evaluation of its cost effectiveness vs fluticasone propionate.Pharmacoeconomics. 1999;16 Suppl 2:i-viii, 1-34. Pharmacoeconomics. 1999. PMID: 10724799 Review. No abstract available.
-
[A rational combination for the treatment of asthma. Salmeterol and fluticasone in one preparation].Pneumologie. 1999 Sep;53(9):426-32. doi: 10.1055/s-1999-9034. Pneumologie. 1999. PMID: 10544652 Review. German. No abstract available.
Cited by
-
Latent myofascial trigger points injection therapy for adult cough variant asthma: A randomized controlled trial.Front Med (Lausanne). 2023 Feb 23;10:937377. doi: 10.3389/fmed.2023.937377. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36910483 Free PMC article.
-
Acrid and Bitter Chinese Herbs in Decoction Effectively Relieve Lung Inflammation and Regulation of TRPV1/TAS2R14 Channels in a Rat Asthmatic Model.Evid Based Complement Alternat Med. 2022 Aug 22;2022:8061740. doi: 10.1155/2022/8061740. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 36045655 Free PMC article.
-
Precision Medicine in Asthma Therapy.Handb Exp Pharmacol. 2023;280:85-106. doi: 10.1007/164_2022_598. Handb Exp Pharmacol. 2023. PMID: 35852633
-
Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER.Respir Res. 2020 Oct 29;21(1):285. doi: 10.1186/s12931-020-01558-y. Respir Res. 2020. PMID: 33121501 Free PMC article. Clinical Trial.
-
A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men.Clin Pharmacol Drug Dev. 2020 Oct;9(7):833-840. doi: 10.1002/cpdd.775. Epub 2020 Jan 20. Clin Pharmacol Drug Dev. 2020. PMID: 31960624 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
